6298-53-9

Usage

Uses

Used in Pharmaceutical Development:
2-(6-oxo-3H-purin-9-yl)acetic acid is used as a key intermediate in the development of pharmaceutical drugs targeting guanine metabolism for the treatment of certain genetic and metabolic disorders.
Used in Research Applications:
In the scientific community, 2-(6-oxo-3H-purin-9-yl)acetic acid is utilized as a research tool to study the regulation of cellular processes and the synthesis and breakdown of nucleic acids, contributing to a better understanding of guanine's role in DNA and RNA metabolism.

InChI:InChI=1/C7H6N4O3/c12-4(13)1-11-3-10-5-6(11)8-2-9-7(5)14/h2-3H,1H2,(H,12,13)(H,8,9,14)

Upstream product

• 87-42-3 6-chloropurine 
• 20128-29-4 2-(6-amino-9H-purin-9-yl)acetic acid 
• 446-86-6 azathioprine 
• 55175-33-2 Ethyl ester of hypoxanthinyl-9-acetic acid 
• 57500-07-9 6-benzyloxypurine 
• 5437-45-6 Benzyl bromoacetate 
• 66224-66-6 adenine 
• 25477-96-7 ethyl 2-(9H-adenin-9-yl)acetate 
• 409304-23-0 [6-(3-methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-purin-9-yl]-acetic acid ethyl ester 

Relevant academic research and scientific papers

Synthesis of 9-substituted derivatives of 6-(nitro-imidazolyl)thiopurines

The synthesis has been achieved of a series of 9-substituted derivatives of 6-(4-nitroimidazol-5-yl)- and 6-(5-nitroimidazol-4-yl)thiopurines by the reaction of 6-(nitroimidazolyl)thiopurines with alkyl and aralkyl halides, haloalcohols, haloacids and the

Modified Nucleobases with Uniform H-Bonding Interactions, Homo- and Hetero-Basepair Bias, and Mismatch Discrimination

Described herein are divalent nucleobases that each binds two nucleic acid strands, matched or mismatched when incorporated into a nucleic acid or nucleic acid analog backbone, such as in a γ-peptide nucleic acid (γPNA). Also provided are genetic recognition reagents comprising one or more of the divalent nucleobases and a nucleic acid or nucleic acid analog backbone, such as a γPNA backbone. Uses for the divalent nucleobases and monomers and genetic recognition reagents containing the divalent nucleobases also are provided.

Synthesis and biological evaluation of new HIV-1 protease inhibitors with purine bases as P2-ligands

Introducing purine bases to P2-ligands might enhance the potency of Human Immunodeficiency Virus-1 (HIV-1) protease inhibitory because of the carbonyl and NH groups promoting the formation of extensive H-bonding interactions. In this work, thirty-three compounds are synthesized and evaluated, among which inhibitors 16a, 16f and 16j containing N-2-(6-substituted-9H-purin-9-yl)acetamide as the P2-ligands along with 4-methoxylphenylsulfonamide as the P2′-ligand, display potent inhibitory effect on the activity of HIV-1 protease with IC50 43 nM, 42 nM and 68 nM in vitro, respectively.

Diversity-oriented chemical modification of heparin: Identification of charge-reduced N-acyl heparin derivatives having increased selectivity for heparin-binding proteins

The diversity-oriented chemical modification of heparin is shown to afford charge-reduced heparin derivatives that possess increased selectivity for binding heparin-binding proteins. Variable N-desulfonation of heparin was employed to afford heparin fract